Two-in-one Digital Radiography-Fluoroscopy system provides low-dose, high-quality images while supporting fast workflow, broadening clinical capacity and increasing room utilization
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ProxiDiagnost N90, its newest premium Digital Radiography-Fluoroscopy (DRF) system. With its ability to perform both nearby fluoroscopy and digital X-rays through a single system, ProxiDiagnost N90 supports high room utilization and increased patient throughput, while also providing outstanding workflow support and patient accessibility. Benefits of the new system for both patients and staff include:
As a dual-use system, ProxiDiagnost N90 meets key dimensions of healthcare’s Quadruple Aim and is a smart choice for healthcare organizations that need a new fluoroscopy solution – particularly those in the U.S. that follow a nearby use method.
Sandra Burghardt
Senior Director of Global Marketing for Diagnostic X-ray at Philips.
“As a dual-use system, ProxiDiagnost N90 meets key dimensions of healthcare’s Quadruple Aim and is a smart choice for healthcare organizations that need a new fluoroscopy solution – particularly those in the U.S. that follow a nearby use method,” said Sandra Burghardt, Senior Director of Global Marketing for Diagnostic X-ray at Philips. “We are setting the bar higher and enabling a confident diagnosis from the first frame. ProxiDiagnost N90 gives radiologists and technologists the ability to capture high-quality still or video images in a way that aligns with their workflow and provides an improved patient experience.” To learn more about Philips’ suite of radiography/fluoroscopy solutions, please visit: https://www.usa.philips.com/healthcare/solutions/radiography 1 Dose rate determined according to IEC 60601-2-54, 203.5.2.4.5.102, System set up: detector format 43 x 43 cm (17 x 17”), patient type children, 0.1 mm Cu + 1 mm Al filter, reduced dose and pulsed slow fluoroscopy mode with 2 pulses/s, Phantom: 5 cm (2 in) PMMA. 2 Relative difference of two reference air kerma rates between system with GCF and system with PCF
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Philips Global Press Office Tel.: +31 631 639 916
You are about to visit a Philips global content page
ContinuePhilips’ ProxiDiagnost N90 provides low-dose, high-quality images while supporting fast workflow, broadening clinical capacity and increasing room utilization